Good news to see positive operating cash flows.
Significant costs in R&D and staff costs but that is expected. R&D will be laced with tax incentives so it good to look at it as a NIL expense, and continued government funding will continue to drive the R&D.
Net $195k outflows for an entire quarter is a great result, especially for a company in its infancy stages.
Hopefully operating cash flows can stay positive, especially with the addition of the I-med contracts going forward.
GLTAH.
Ann: Quarterly Activity Report and Appendix 4C for Q3 FY2022, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
-0.020(3.77%) |
Mkt cap ! $217.5M | |||
| Open | High | Low | Value | Volume |
| 52.5¢ | 52.5¢ | 50.5¢ | $128.8K | 249.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 28149 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 22153 | 2 |
View Market Depth
| Last trade - 10.36am 07/10/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |